Jeff Smith MP: speeches

Speeches

• 8 Sept 2026 · Health Bill · Hansard source

  More

  Clauses 5 and 6 place duties on the Secretary of State to promote patient involvement, patient choice and innovation. My new clauses 86 and 87 would apply those principles to psychedelic-assisted therapy treatments involving schedule 1 controlled substances. I have been pleased to be a trustee of the charity Drug Science, which has allowed me to talk to researchers who are looking at therapeutic treatments using what are called psychedelic drugs. Around the world there is growing evidence of the successful treatment of post-traumatic stress disorder, trauma, mental health issues and end-of-life distress using these drugs. For some patients they are absolutely revelatory. They change lives for the better and can relieve the burden of those conditions on the wider health service. Researchers tell me, however, that the barriers the current system puts in place really restrict research. Research involving schedule 1 controlled substances generally requires a Home Office licence, and the bureaucracy and inertia in the system adds delay, cost and an administrative burden to the extent that research grants are being lost because of delays. The issue has already been considered. In 2023 the Home Affairs Committee recommended urgently moving psychedelic drugs to schedule 2 in order to facilitate research. Later that year, the Advisory Council on the Misuse of Drugs recommended that research using schedule 1 drugs in universities and hospitals should be exempt from the Home Office domestic licencing requirement and should instead operate under schedule 2 controls. In 2025 the Government accepted the ACMD recommendations in principle. There is supposed to be a pilot of a proposed extension to test operational feasibility, but that has not happened. The Government said the policy work was under way and that further plans would be published in due course, but without a timetable for implementation. My new clause 86 would make it happen. Other jurisdictions are ahead of us on this issue. The US Department of Defence and the US Department of Veterans Affairs are already funding clinical trials for military personnel and veterans. New clause 87 concerns compassionate access to treatment. International research has identified potential in some treatment-resistant psychiatric conditions and end-of-life distress. There is international precedent. The 2022 Canadian special access programme has allowed clinicians to request restricted drugs, including psilocybin and MDMA, to treat those conditions. We can learn from those experiences. Finally, I am grateful to the Minister for meeting me to discuss these issues, and for her agreement on the principle of enabling the clinical research of these drugs and her commitment to get back to me to outline how the Government will take them further.

• 9 Jul 2026 · Israeli Settlements: Trade Ban · Hansard source

  More

  My hon. Friend is absolutely right and puts it better than I did. We can figure out how to make a ban work once we have committed to the principle, and there are ways of doing it. As we have heard today, the Government already have processes in place to distinguish between goods coming from Israel and the OPT as a result of the processes on preferential access for Israeli goods, and we can build on that experience. We have heard that other countries are already instigating such measures, and we can learn from their experience. A settlement trade ban is no longer a marginal or unrealistic demand; it is becoming a mainstream response. A ban on trade with settlements would not, on its own, bring peace to Israelis and Palestinians, but it would ensure that Britain is not contributing to an unlawful situation that the world’s highest court has concluded all states have a duty not to support. It would demonstrate that our principles are reflected not only in our words, but in our actions.